HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer

Abstract excerpt

Despite the outstanding clinical results of immune checkpoint blockade (ICB) in melanoma and other cancers, clinical trials in breast cancer have reported low responses to these therapies. Current efforts are now focused on improving the treatment efficacy of ICB in breast cancer using new combination designs such as molecularly targeted agents, including histone deacetylase inhibitors (HDACi). These epigenetic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Click Chemistry and Applications
• Share to Histone Deacetylase Inhibitors Research
• Share to Peptidase Inhibition and Analysis